NCT00273871View on ClinicalTrials.gov

Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients

PHASE3CompletedINTERVENTIONAL

Enrollment

190

Participants

Timeline

Start Date

January 31, 2002

Study Completion Date

September 30, 2006

Conditions

Graft RejectionKidney FailureKidney Transplantation

Interventions

DRUG

Cyclosporin or tacrolimus

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00273871 - Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients | Biotech Hunter | Biotech Hunter